[Experimental study of the oral and injectable forms of a new antidepressive agent (doxepine) in 40 patients].
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D001007:Anxiety / Q000188:drug therapy; D001714:Bipolar Disorder / Q000188:drug therapy*; D000697:Central Nervous System Stimulants / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003863:Depression / Q000188:drug therapy*; D003865:Major Depressive Disorder / Q000188:drug therapy*; D003990:Dibenzoxepins / Q000008:administration & dosage* / Q000009:adverse effects; D004338:Drug Combinations; D004361:Drug Tolerance; D004562:Electrocardiography; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D006993:Hypnotics and Sedatives / Q000008:administration & dosage; D007024:Hypotension, Orthostatic / Q000139:chemically induced; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D013610:Tachycardia / Q000139:chemically induced
D000697:Central Nervous System Stimulants; D003990:Dibenzoxepins; D004338:Drug Combinations; D006993:Hypnotics and Sedatives
Expérimentation de la forme orale et injectable d'un nouvel antidépresseur (doxépine) chez 40 malades.